
News|Articles|October 1, 2004
High-dose simvastatin fails to achieve primary end point in trial of ACS
Initiating high-dose simvastatin (Zocor, Merck) early after an acute coronary syndrome (ACS) event does not result in significantly superior clinical outcomes compared to delayed initiation of low-dose simvastatin.This major finding of phase Z of the A to Z Trial is in contrast to the results of 2 previous clinical trials in which aggressive therapy with atorvastatin (Lipitor, Pfizer) was found to be superior to less aggressive statin therapy in reducing the risk of adverse clinical events in ACS patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Modernizing Pharmacy Benefit Administration: Addressing Legacy System Friction for Health Plans
2
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
3
Vitiligo is associated with mental heath conditions, other autoimmune diseases
4
Make lab monitoring of patents taking isotretinoin less routine, more based on symptoms
5
































